CD8A and neoplasm: Tumor-bearing mice treated with the anti-PVRIG mAb presented a significantly greater number of NK cells (NKp46+ in CD45+ cells) and upregulation of CD107a, while the number of total CD8+ T cells remained unchanged after the first dose (Fig. 4b).